Source: Tech – South China Morning PostBiotechnology firm Insilico Medicine said its new drug for lung disease, designed with the help of artificial intelligence (AI), showed positive results in the latest clinical trials, as the company pushes for a public listing in Hong Kong.
Insilico found that its new small-molecule drug candidate, rentosertib, designed with its AI platform Chemistry42, was “generally safe and potentially effective” for treating idiopathic pulmonary fibrosis (IPF), according to its phase 2A clinical trial…Read More